<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03485534</url>
  </required_header>
  <id_info>
    <org_study_id>DW_TEN001</org_study_id>
    <nct_id>NCT03485534</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety to Tenofovir Disoproxil in Chronic Hepatitis B Patients</brief_title>
  <acronym>HBV</acronym>
  <official_title>Evaluate the Efficacy and Safety of Switching to Tenofovir Disoproxil From Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients Who Pretreated With Tenofovir Disoproxil Fumarate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>C&amp;R Research, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy and safety of switching to Tenofovir Disoproxil from
      Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients who pretreated with Tenofovir
      Disoproxil Fumarate.

      In Open-Label, phase 3 studies, we randomly assigned patients with hepatitis B e antigen
      (HBeAg)-negative or HBeAg-positive chronic HBV infection to receive Tenofovir Disoproxil or
      Tenofovir Disoproxil Fumarate (ratio, 2:1) once daily for 48 weeks
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tenofovir Disoproxil and Tenofovir Disoproxil Fumarate is a nucleotide analogue and a potent
      inhibitor of human immunodeficiency virus type 1 reverse transcriptase and hepatitis B virus
      (HBV) polymerase.

      The primary efficacy end point at week 48 of this study was defined as the combination of an
      HBV DNA level of less than 400 copies per milliliter and histologic improvement .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2017</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-label, randomized, Parallel</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBV DNA inhibition</measure>
    <time_frame>48weeks</time_frame>
    <description>plasma HBV DNA level of less than 400 copies per milliliter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>viral suppression</measure>
    <time_frame>24weeks</time_frame>
    <description>an HBV DNA level of &lt;400 copies per milliliter</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">189</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Tenofovir Disoproxil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir Disoproxil 245mg, a daily dose for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tenofovir Disoproxil Fumarate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tenofovir Disoproxil Fumarate 300mg, a daily dose for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Disoproxil Fumarate</intervention_name>
    <description>Viread 300mg</description>
    <arm_group_label>Tenofovir Disoproxil Fumarate</arm_group_label>
    <other_name>Viread</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Disoproxil</intervention_name>
    <description>Virehepa 245mg</description>
    <arm_group_label>Tenofovir Disoproxil</arm_group_label>
    <other_name>Virehepa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hepatitis B virus (HBV) infection, defined as positive serum hepatitis B
             s-antigen (HBsAg) for at least 6 months.

          -  HBeAg negative and HBeAb positive at screening

        Exclusion Criteria:

          -  Pregnant women, women who are breast feeding, or women who believe they may wish to
             become pregnant during the course of the study

          -  Males and females of reproductive potential who are unwilling to use an effective
             method of contraception during the study.

          -  Decompensated liver disease defined as conjugated bilirubin &gt; 1.5 x ULN, prothrombin
             time (PT) &gt; 1.5 x ULN, platelets &lt; 75,000/mL, serum albumin &lt; 3.0 g/dL, or prior
             history of clinical hepatic decompensation (eg, ascites, jaundice, encephalopathy,
             variceal hemorrhage)

          -  Significant renal, cardiovascular, pulmonary, or neurological disease

          -  currently receiving therapy with immunomodulators (eg, corticosteroids, etc.),
             investigational agents, nephrotoxic agents, or agents susceptible of modifying renal
             excretion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Youngsuk Lim, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mijung Song</last_name>
    <phone>02-550-8368</phone>
    <email>mjsong257@daewoong.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Youngsuk Lim, phD</last_name>
      <phone>02-550-8368</phone>
      <email>mjsong257@daewoong.co.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2018</study_first_submitted>
  <study_first_submitted_qc>March 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2018</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

